ClinicalTrials.Veeva

Menu

Drug-Drug Interaction Study of MRA in Patient With Rheumatoid Arthritis (RA)

Chugai Pharmaceutical logo

Chugai Pharmaceutical

Status

Completed

Conditions

Rheumatoid Arthritis

Treatments

Drug: MRA(Tocilizumab)

Study type

Interventional

Funder types

Industry

Identifiers

NCT00144560
MRA220JP

Details and patient eligibility

About

This is an open-label, clinical pharmacology study to investigate drug-drug interaction in patients with RA.

Enrollment

31 patients

Sex

All

Ages

20 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion criteria

  • Patients who are diagnosed with RA according to the 1987 American College of Rheumatology (ACR) classification criteria
  • Patients who contracted RA at least 6 months prior

Exclusion criteria

  • Patients with Class IV Steinbrocker functional impairment at enrollment.
  • Patients who have been treated for the underlying disease with a biological agent, such as infliximab or etanercept and have been receiving treatment with leflunomide, within 12 weeks before initiation of treatment with the probe drug

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Single Group Assignment

Masking

None (Open label)

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems